ROCHESTER, N.Y., April 2 /PRNewswire/ -- Genencor today announced that it has granted Pfizer a non-exclusive license to technology that enhances the level of expression of secreted polypeptides (proteins) in microorganisms for use in the development of protein therapeutics. The technology described in United States Patents #6,544,792 and #6,642,027 improves processes for protein production in microorganisms which in turn may reduce the cost of developing protein-based drugs. The terms of the agreement were not disclosed.
"Genencor's ability to improve the efficiency of protein production is widely applicable to many industries," said Michael V. Arbige, Genencor's Executive Vice President for Innovation. "As the cost of protein manufacturing has long been a potential barrier to therapeutic development in some cases, Pfizer's use of this technology may create opportunities to develop new and more effective therapies."
Arbige added that with more than 25 years in the design, modification and manufacture of proteins, Genencor offers an extensive portfolio of technologies that are widely used in a diversity of fields. "We're pleased to collaborate with leading industry innovators to expand their technology options to help improve their products."
Genencor, a division of Danisco A/S, is a leading industrial biotechnology company that develops innovative enzymes and bioproducts to improve the performance and reduce the environmental impact of the cleaning, textiles, fuels and chemicals industries.
CONTACT: Angela Blackwell, +1-585-256-6973, Angela.Blackwell@danisco.com,for Genencor